LianBio

OTCPK:LIAN.Y Stock Report

Market Cap: US$12.0m

LianBio Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Adam Stone

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2.5yrs
CEO ownershipn/a
Management average tenure2.5yrs
Board average tenure5yrs

Recent management updates

Recent updates

Seeking Alpha • Feb 23

With No Cure In Sight, Drugs Firm LianBio Begins Exit Strategy

Summary The biotech, which obtained rights to novel drugs for use in the Chinese market, has announced a plan to wind up its business and delist from the Nasdaq just four years after being founded. The drug maker will sell its remaining pipeline assets, phase out ongoing clinical trials and pay a special dividend of $4.80 per share. LianBio has failed to deliver any product to the market since it was established in 2020. Read the full article on Seeking Alpha
Analysis Article • Jul 20

LianBio (NASDAQ:LIAN) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Apr 05

We're Hopeful That LianBio (NASDAQ:LIAN) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Dec 20

We Think LianBio (NASDAQ:LIAN) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Sep 02

Companies Like LianBio (NASDAQ:LIAN) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • May 17

Will LianBio (NASDAQ:LIAN) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Mar 03

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

The company is focused on bringing innovative therapies to China and major Asian markets through partnerships with other biotech/pharma companies. China is the second-largest pharmaceutical market in the world ($220 billion/year), after the U.S. The stock is significantly undervalued and up 35% from its early February low.
Analysis Article • Feb 01

Here's Why LianBio (NASDAQ:LIAN) Must Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

CEO

Adam Stone (46 yo)

2.5yrs
Tenure
US$62,073
Compensation

Mr. Adam Leo Stone is Chief Investment Officer of Perceptive Advisors LLC from March 2025. He joined the Perceptive Advisors LLC in 2006. He was Chief Investment Officer & Head of Research of Perceptive Ad...

Leadership Team

NamePositionTenureCompensationOwnership
Konstantin Poukalov
Founder & Executive Chairman6.7yrsUS$62.07kno data
Adam Stone
Interim CEO & Director2.5yrsUS$62.07kno data
Ehong Gu
Interim CFO2.5yrsno datano data
Ji Chen
Senior VP & General Counselno datano datano data
Brianne Puglisi
Chief Business Officer4.8yrsUS$2.69mno data
Levvy Lv
Senior VP & Global Head of Developmentno datano datano data
2.5yrs
Average Tenure
42yo
Average Age

Experienced Management: LIAN.Y's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Konstantin Poukalov
Founder & Executive Chairman6.7yrsUS$62.07kno data
Adam Stone
Interim CEO & Director6.7yrsUS$62.07kno data
Tassos Anastasios Gianakakos
Independent Director5.8yrsUS$128.07kno data
Neil Kumar
Director6.7yrsno datano data
Elliott Levy
Member of Scientific Advisory Board4.2yrsno datano data
Mathias Hukkelhoven
Member of Scientific Advisory Board4.2yrsno datano data
Wei Chen
Independent Director4.2yrsUS$285.89kno data
Zhao Yan
Member of Scientific Advisory Board4.2yrsno datano data
5.0yrs
Average Tenure
53yo
Average Age

Experienced Board: LIAN.Y's board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/17 01:09
End of Day Share Price 2026/06/15 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

LianBio is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Ziyi ChenGoldman Sachs
Michael YeeJefferies LLC